Results 151 to 160 of about 105,877 (293)

piR‐RCC Suppresses Renal Cell Carcinoma Progression by Facilitating YBX‐1 Cytoplasm Localization

open access: yesAdvanced Science, EarlyView.
PIWI‐interacting RNAs (piRNAs), a novel category of small non‐coding RNAs, have been implicated in the development of various diseases. This study explores the tumor‐suppressive mechanism of a downregulated piRNA (designated piR‐RCC) in renal cell carcinoma (RCC), and provides a delivery strategy targeting RCC tumor by constructing a cell membrane ...
Ruyue Wang   +16 more
wiley   +1 more source

Intravenous Lidocaine for Refractory Chronic Orofacial Pain : Two case reports and a literature review

open access: yesSultan Qaboos University Medical Journal, 2008
This report presents the results of treatment of two adults, at the Pain Center of Montreal General Hospital, Canada, with intravenous lidocaine for intractable orofacial pain.
Abdulaziz Almahrezi   +4 more
doaj  

RIG‐I‐Inducing Small Molecules Potently Inhibit HMA‐Resistant AML Through Igniting the Overloaded dsRNA Arsenal

open access: yesAdvanced Science, EarlyView.
This study reveals a novel mechanism of resistance to DNA hypomethylating agents (HMAs) in acute myeloid leukemia (AML), and identifies all‐trans retinoic acid (ATRA) and tamibarotene (TAM) as potent agents that overcome HMA resistance by reactivating the interferon anticancer immune response. The findings offer promising therapeutic strategies for HMA‐
Xueqin Chen   +18 more
wiley   +1 more source

Tumor Microenvironment Triggered In Situ Coagulation of Supramolecularly Engineered Platelets for Precise Tumor Embolization

open access: yesAdvanced Science, EarlyView.
Occlusion of tumor blood vessels represents a promising yet challenging approach in cancer treatment. Herein, supramolecularly engineered platelets conjugated with morphology‐transformable nanoparticles is developed for precise tumor embolization. The engineered platelets actively accumulate at tumor sites following induced blood vessel injury.
Junyan Li   +9 more
wiley   +1 more source

Adverse Reaction Following Intravenous Immunoglobulin in Primary Immunodeficiency Patients

open access: yesJournal of Mazandaran University of Medical Sciences, 2007
Background and Purpose: Intravenous immunoglobulin is used for primary immunodeficiency disorders. There have been some reports that intravenous immunoglobulin causes side effects.
J. Ghaffari, M.D.+   +3 more
doaj  

PSMD14 Stabilizes SLC7A11 to Ameliorate Glucocorticoid‐Induced Osteoporosis by Suppressing Osteocyte Ferroptosis

open access: yesAdvanced Science, EarlyView.
Glucocorticoid‐induced osteoporosis (GIOP) triggers osteocyte ferroptosis via SLC7A11 degradation. PSMD14 stabilizes SLC7A11 by counteracting glucocorticoid‐driven ubiquitination, preserving cystine uptake and glutathione synthesis. AAV‐mediated PSMD14 delivery or its agonist Pantethine rescues osteocyte survival and bone loss in GIOP mice.
Yifeng Shi   +20 more
wiley   +1 more source

Tumor‐Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion

open access: yesAdvanced Science, EarlyView.
This study identifies Globo H ceramide (GHCer) as a novel immune checkpoint molecule that suppresses the activation of conventional T lymphocytes while promoting the differentiation and function of regulatory T cells. The immunosuppressive effects of GHCer are mediated through the activation of the A2AR/cAMP/PKA pathway, which involves its interactions
Jing‐Yan Cheng   +13 more
wiley   +1 more source

Ultrasound‐Induced Nitric Oxide‐Propelled Nanomotor for Multimodal Theranostics of Cancer with Deep Penetration and Extended Lifetime

open access: yesAdvanced Science, EarlyView.
A hollow nanomotor (PM‐HMSN/Arg) propelled by ultrasound‐triggered nitric oxide (NO) was developed. The nanomotor employs a “tethering‐relaxing‐drilling” mechanism to overcome biological barriers, enabling multimodal theranostics of cancer with deep penetration and extended lifetime.
Xue Xu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy